Clofarabine Targets the Large Subunit (α) of Human Ribonucleotide Reductase in Live Cells by Assembly into Persistent Hexamers  by Aye, Yimon et al.
Chemistry & Biology
Brief CommunicationClofarabine Targets the Large Subunit (a)
of Human Ribonucleotide Reductase
in Live Cells by Assembly into Persistent Hexamers
Yimon Aye,1 Edward J. Brignole,1,3,4 Marcus J.C. Long,5 Johnathan Chittuluru,4 Catherine L. Drennan,1,2,3
Francisco J. Asturias,4 and JoAnne Stubbe1,2,*
1Department of Chemistry
2Department of Biology
3Howard Hughes Medical Institute
Massachusetts Institute of Technology, Cambridge, MA 02139, USA
4Department of Cell Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
5Graduate Program in Biochemistry and Biophysics, Brandeis University, Waltham, MA 02454, USA
*Correspondence: stubbe@mit.edu
http://dx.doi.org/10.1016/j.chembiol.2012.05.015SUMMARY
Clofarabine (ClF) is a drug used in the treatment
of leukemia. One of its primary targets is human
ribonucleotide reductase (hRNR), a dual-subunit,
(a2)m(b2)n, regulatory enzyme indispensable in de
novo dNTP synthesis. We report that, in live mam-
malian cells, ClF targets hRNR by converting its
a-subunit into kinetically stable hexamers.We estab-
lishedmammalian expression platforms that enabled
isolation of functional a and characterization of
its altered oligomeric associations in response to
ClF treatment. Size exclusion chromatography and
electron microscopy documented persistence of
in-cell-assembled-a6. Our data validate hRNR as
an important target of ClF, provide evidence that
in vivo a’s quaternary structure can be perturbed
by a nonnatural ligand, and suggest small-mole-
cule-promoted, persistent hexamerization as a
strategy to modulate hRNR activity. These studies
lay foundations for documentation of RNR oligo-
meric state within a cell.
INTRODUCTION
Alterations of quaternary states of a protein can change its func-
tion dramatically (Nooren and Thornton, 2003; Arkin and Wells,
2004; Piehler, 2005). Although many methods exist to establish
protein oligomeric equilibria in vitro, validating the existence of
these oligomers and their relevance in vivo is often challenging,
despite its importance (Piehler, 2005). One specific case where
these issues remain unresolved is ribonucleotide reductases
(RNRs), highly regulated enzymes that catalyze the conversion
of nucleoside 50-diphosphates (NDPs) to deoxynucleotides
(Stubbe and van Der Donk, 1998; Stubbe et al., 2003; Nordlund
and Reichard, 2006).
Human (h)RNRs belong to the class Ia family of RNRs that
require two subunits (a2)m and (b2)n or p53(b2)n, which form, asChemistry & Biology 19,yet unresolved, active complex(es) proposed to be a2b2, a6b2,
and/or a6b6 (Kashlan and Cooperman, 2003; Rofougaran et al.,
2006; Fairman et al., 2011; Hofer et al., 2012). In addition to
the NDP-binding, catalytic (C) site, (a2)m possesses two well-
characterized allosteric sites. The activity (A) site, within the
N-terminal ATP-cone-domain, binds either ATP, activating
RNR activity, or dATP, inhibiting it. The specificity (S) site, at
the a2 interface, binds dNTP/ATP, modulating the substrate
preference at the C site (Fairman et al., 2011). In vitro studies
on eukaryotic RNRs indicate that the dATP-inhibited complex
is a6 (Kashlan and Cooperman, 2003; Rofougaran et al., 2006;
Fairman et al., 2011; Aye and Stubbe, 2011), with its arrange-
ment as a trimer-of-dimers demonstrated by electron micros-
copy (EM) (of particles preserved in stain) and 6.6 A˚-resolution
X-ray crystallography of the Saccharomyces cerevisiae RNR
(Fairman et al., 2011).
The importance of hRNR in dNTP pool homeostasis (Zhou and
Elledge, 2000; Thelander, 2007; Bester et al., 2011) has rendered
it a successful drug target (Shao et al., 2006), and drug-induced
alterations in oligomeric equilibria have been demonstrated
in vitro (Wang et al., 2007; Aye and Stubbe, 2011). We have
recently shown that di- and triphosphates of the clinically used
leukemia-drug ClF (Clofarabine, Clolar; Figure 1) are both revers-
ible inhibitors of hRNR, binding to the C and A sites of a, respec-
tively (Aye and Stubbe, 2011). Inactivation is accompanied by
a-hexamerization that occurs independently of allosteric effec-
tors and (b2)n. Size exclusion chromatography (SEC) studies
further demonstrated that ClFD(T)P-induced hexamers are
kinetically stable in the absence of inhibitors in the SEC running
buffer. These hexamers thus display fundamentally distinct
kinetic properties from the dATP-induced a6 (Kashlan and Coop-
erman, 2003; Rofougaran et al., 2006; Fairman et al., 2011; Aye
and Stubbe, 2011), which rapidly dissociate to an equilibrium
mixture of lower order oligomers when the dATP is omitted
from the elution buffer (Fairman et al., 2011; Aye and Stubbe,
2011).
We now report biochemical and structural evidence that
hexamers generated subsequent to RNR inhibition by ClFD(T)P
in vitro (Aye and Stubbe, 2011) are also assembled in ClF-treated
cultured live cells. Initially, crosslinking studies on homogeneous799–805, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 799
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Figure 1. hRNR Is a Principal Target of ClF
ClF enters the cell by passive diffusion and/or via
nucleoside transporters and is rapidly phosphor-
ylated (Bonate et al., 2006; Zhenchuk et al., 2009).
ClFDP andClFTP both target hRNR (a2)m, resulting
in the depletion of dNTP pools including dCTP.
Reduction of the latter potentiates production
of ClF metabolites by removing negative feedback
inhibition of deoxycytidine kinase, dCK, an en-
zyme that catalyzes monophosphorylation of ClF.
Diminution of overall dNTP pool sizes amplifies
misincorporation of ClFTP into DNA by DNA
polymerase-a and –ε, where it functions as a chain
terminator. Induction of apoptosis is thought to be ultimately responsible for anticancer activity. ClFTP is a rapid reversible inhibitor of a via binding to the activity
(A) site (Ki = 40 nM) and ClFDP is a slow-release reversible inhibitor (Ki* = 17 nM, t1/2 = 23 min) of a via binding to the catalytic (C) site, and both cause a hex-
amerization (Aye and Stubbe, 2011). Blue and green ellipses represent (a2) and (b2 or p53b2), respectively.
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Clofarabine Induces hRNR Hexamers in Live Cellsrecombinant a at concentrations measured in vivo (A˚kerblom
et al., 1981; Ha˚kansson et al., 2006; present study) showed, by
gel analysis, that in the presence of ClFD(T)P, a was almost
exclusively hexameric. However, similar studies to demonstrate
hexamerization of the endogenous mammalian a in highly dilute
lysates resulting from ClF-treated COS-1 cells, proved to be
challenging because of very low endogenous a expression.
Thus in an effort to assess the oligomeric state of a in vivo, the
protein was first overexpressed minimally (3.5-fold above the
endogenous level as judged by western blot analysis). Under
these conditions, a from ClF-treated live COS-1 cells, subse-
quent to crosslinking in the resulting lysates, underwent a gel-
shift to a molecular weight consistent with a hexamers and
similar to that characterized in vitro (Aye and Stubbe, 2011). To
obtain biochemical and structural data in support of a-hexame-
rization, we then constructed a bicistronic reporter cassette that
simultaneously overexpressed a fluorescent protein, Discosoma
Red (DsRed), and His6-a (Wang et al., 2007; Aye and Stubbe,
2011). This platform enabled assessment of the oligomeric state
of native a by SEC and single particle EM, subsequent to cell
lysis and affinity purification. Our data together validate the
current model that hRNR is a target of ClF metabolites prior to
the onset of cytotoxicity (Bonate et al., 2006). Remarkably,
targeting hRNR results in the in-cell assembly of persistent
hexamers that are also shown in vitro to remain stable subse-
quent to inhibitor dissociation. We provide the first evidence,
to our knowledge, that the oligomeric state of (a2)m in live cells
can be perturbed by an external ligand.
RESULTS
Crosslinking Studies on (a2)m Expressed at
Near-Endogenous Levels Provide Preliminary Evidence
for Drug-Induced Hexamerization in Cultured Cells
The a subunit of hRNR has a half-life of 15–24 hr and is present
throughout the cell cycle in proliferating cells at very low levels
(A˚kerblom et al., 1981; Engstro¨m et al., 1984, 1985; Ha˚kansson
et al., 2006; Thelander, 2007). The amount of a in nonsynchron-
ized cells has been estimated to be 0.07% wt/wt of total
proteins in 3T6 cells (A˚kerblom et al., 1981) and 0.04% in
COS-1 cells (present study, Figure S1A available online). These
low expression levels technically limit the isolation and the
biochemical and structural characterization of the oligomeric
state of a in the cell.800 Chemistry & Biology 19, 799–805, July 27, 2012 ª2012 Elsevier LAs a prelude to this goal, we initially attempted native gel
electrophoresis on hexameric His6-a generated in vitro as previ-
ously described (Aye and Stubbe, 2011). However, a6 failed to
penetrate a 4% polyacrylamide gel. We then tested chemical
crosslinking in an effort to covalently stabilize the hexameric
state for analysis by denaturing gel electrophoresis. BS-3
[Bis(sulfosuccinimidyl) suberate] (Figure S1B-A) was chosen as
the crosslinker and the optimized conditions resulted in a shift
of a from 92 kDa (monomer of a) to >500 kDa (consistent with
hexamer of a) (Figure S1B-B). Hexamerization was detected
over a range of a concentrations (5 nM to 5 mM) in the presence
of BS3 (1–3 mM), subsequent to an incubation period of as early
as 1 min at 37C. Only when the samples had been treated with
ClFD(T)P and BS3 were the shifts observed. In a control with no
inhibitor, or with inhibitor and no BS3, the large-molecular-
weight species was absent. In addition, crosslinked complexes
with an approximate molecular weight of a dimers were also de-
tected (to < 20%of total a) in the presence or absence of inhibitor
(Figure S1B-B). The observed gel shift thus serves as a diag-
nostic marker for a hexamerization and provided the impetus
to use crosslinking as an initial strategy to examine the ClF-
induced quaternary state perturbation of (a2)m in mammalian
cells.
Experiments on COS-1 cells treated with ClF to detect hex-
amerization of the endogenous protein proved considerably
more challenging. Ultimately, success was achieved using a
mammalian expression plasmid (monocistronic cassette, Fig-
ure 2A and Table S1A) transfected into COS-1 cells that allowed
ectopic expression of untagged hRNR a at levels 3.5-fold
above the endogenous level (Figure S1B-C). Because ClFD(T)
P-induced oligomerization is (b2)n independent (Aye and Stubbe,
2011), only a was part of the construct. The expressed a in the
transfected samples had activity 10-fold higher than the non-
transfected samples (Figure 2B and Figure S1A-A). The basis
behind the 2–3-fold higher lysate activities, relative to the fold
increment in expression level assessed by western blot (Fig-
ure S1B–S1C), is not well understood.
Using the crosslinking method described above, the ectopic
expression of hRNR a at 3.5-fold above the endogenous levels
enabled, as shown below, the demonstration of a-hexameriza-
tion within the cell in response to ClF treatment. Throughout
this work, all studies were carried out in a time frame where
essentially all cells are viable (Figures S1C and S1D-A), to mini-
mize the possibility that results are affected by ClF-inducedtd All rights reserved
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Figure 2. Initial Crosslinking Studies on In-Cell Relevance of a-Hexamerization and a Bicistronic Reporter Cassette for Expression/Rapid
Purification of hRNR (a2)m from Mammalian Cells
(A) hRNR (a2)m expression platforms (Tables S1A and S1B): Monocistronic cassette results in expression of untagged protein; Cassette A of DsRed and His6-a;
Cassette B of DsRed and eGFP-a. Merged confocal fluorescence images of live HeLa (1) and COS-1 (2) cells transfected with Cassette B. Scale bar in (1) and (2)
each corresponds to 10 mm.
(B) Protein content, fold-overexpression, and activities in lysate (and of isolated, where applicable) of untagged-, His6-. and eGFP-a ectopically expressed in
COS-1 cells, subsequent to transient transfection with either monocistronic cassette (Table S1A) or bicistronic reporter cassettes A or B (Table S1B). Corre-
sponding values for the endogenous a were shown for comparison. Data, where applicable, are represented as mean ± SD. See also Figures S1A and S1B-C.
(C) a-Hexamerization, subsequent to crosslinking in lysates, in response to ClF (50 nM) treatment of live COS-1 cells expressing untagged-a at 3.5-fold above the
endogenous levels. Lanes a and b, results from BS3 (1 mM) treatment of the lysates (0.1 mg/ml) from ClF-treated (a) and untreated (b) cells. Lane c, recombinant
His6-a (0.15 mg/ml) treated in vitro with BS3 and subjected to identical sample preparation procedures as for lysates. Lane d, identical to lane c except additional
presence of ClFTP (effectively, crosslinked a6 standard; see Figure S1B-B for in vitro characterization).
(D) SDS-PAGE of steps involved in His6-a purification from COS-1 cells transfected with Cassette A. Lanes (left to right): lysate; supernatant after TALON
incubation; wash 1; wash 2; elution; MW ladder. Arrows indicate His6-a (92 kDa) and DsRed (27 kDa). See also Figure S1D.
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Clofarabine Induces hRNR Hexamers in Live Cellsapoptosis (Carson et al., 1992; Bonate et al., 2006; Zhenchuk
et al., 2009). The results obtained are therefore most likely
a consequence of the direct interaction between (a2)m and
ClFD(T)P (Aye and Stubbe, 2011). Transfected COS-1 cells
were treated with ClF (50 nM), were incubated for 3 hr, and
were compared with control experiments under identical condi-
tions. The choices of nucleoside concentration and incubation
time were guided by the viability data of ClF-treated cells relative
to untreated controls (Figure S1C) and by previous pharmaco-
logical studies (Parker et al., 1991; Carson et al., 1992; Xie
and Plunkett, 1995, 1996; Lotfi et al., 1999; Bonate et al., 2006;
Zhenchuk et al., 2009). Subsequently, lysates from treated and
untreated cells were diluted (25–2503) prior to treatment with
the crosslinker. Initial tests were performed under different dilu-
tions, because crosslinking of pre-existing a6 (an intramolecular
reaction) should not be influenced by dilution, whereas unde-
sired crosslinking to other proteins in the crude extract wouldChemistry & Biology 19,be minimized. A lysate concentration of 0.1 mg/ml was found
to be optimum. The high dilution also required that lysate
solutions be lyophilized and ethanol-precipitated prior to
western blot analysis. Under these conditions, incubation with
BS3 (1 mM) over 1 min at 37C showed that >95% ± 1% of
a is present in hexameric form in the treated cells, whereas
<1% of a is hexameric in the control (Figure 2C). These data
provide preliminary evidence for the formation of hexameric
a within a cell upon ClF treatment.
Reporter Assay Advances Optimization of hRNR
Expression in Live Mammalian Cells
To further characterize ClF-induced hexamerization of a in vivo,
expression of sufficient amounts of protein and rapid affinity
isolation were required. Because N-terminal His6-tagging of
a has been previously shown not to affect a’s activity or
ClFD(T)P-promoted hexamerizations (Aye and Stubbe, 2011),799–805, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 801
Figure 3. ClF Treatment Results in Persistent a6 in Live Cells
(A–I) Cells are analyzed by size exclusion chromatography (SEC) (AD) and single particle electron microscopy (EM) (EI).
(A and B) SEC elution profiles of TALON-purified (a2)m,monitored by A280nm and A260nm, fromClF-treatedCOS-1 cells (A) and untreatedCOS-1 cells (B). Themajor
peak in (A) elutes at 17 min and is proposed to be a6 by comparison with in vitro- ClFTP and ClFDP-treated r-His6-a (inset in A) and standard proteins of known
molecular weight (Figure S2C-F). Note the absence of this peak in (B).
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Clofarabine Induces hRNR Hexamers in Live Cellsectopic expression of His6-a in mammalian cells was pursued.
An internal ribosomal entry site (IRES)-based cassette encoding
both DsRed and His6-a was designed (Cassette A, Figure 2A
and Table S1B). Because both DsRed and His6-a are derived
from a single mRNA transcript downstream of the CMV
promoter, the presence of one mandates that of the other (Yen
et al., 2008). The intrinsic coexpression of the fluorescent
marker, DsRed, allowed rapid optimization of the transfection
efficiency. This strategy enabled overexpression of a at the
levels sufficient for biochemical analysis [29-fold above the
endogenous in COS-1 cells, as judged by western blot (Fig-
ure S1B-C)]. We reasoned that the shift to the hexamer would
not be negatively impacted by high overexpression of a,
because inhibitor-induced oligomerization is (b2)n independent
(Aye and Stubbe, 2011). Furthermore, because mammalian
RNR activity in vivo is limited by (b2)n because of the constitutive
expression of (a2)m throughout the cell cycle (Thelander, 2007),
minimum perturbation to the native system was expected,
despite the high level of a expression. His6-a was additionally
shown to be ectopically expressed in HeLa and HEK293 cell
lines while maintaining good cell viability (Figure S1D-A). We
chose COS-1 as our representative cell line. The a expressed
was shown to be functional by lysate activity assays (Figure 2B
and Figure S1A). As previously observed for COS-1 cells
transfected with the monocistronic plasmid (Figure 2A and
Table S1A), lysate activities from cells expressing DsRed and
His6-a also are higher than what was expected from the
corresponding level of protein overexpression (Figure 2B and
Figure S1B-C).
As an additional proof-of-principle for a functional IRES-
mediated hRNR expression platform, an alternative dual-
reporter cassette B (Figure 2A and Table S1B) was constructed
that directly reports on a expression levels relative to the
DsRed using FACS. Lysates of ectopically expressed en-
hanced green fluorescent protein-fused a (eGFP-a) from
COS-1 cells have reductase activity similar to lysates contain-
ing His6-a (Figure 2B), as do recombinantly expressed and puri-
fied His6-a and His6-eGFP-a from Escherichia coli (Table S1C
and Figure S1E). Preferential nuclear exclusion of GFP-fused
a observed in live COS-1 and HeLa cells (Figure 2A) is con-
sistent with previously reported data using cell fractionation
and immunofluorescence (Engstro¨m et al., 1984; Pontarin
et al., 2008).
Rapid Affinity Purification Affords Isolation of
Ectopically Expressed Active hRNR a
E. coli-expressed recombinant (r)-His6-a was previously purified
to homogeneity using a cobalt-affinity chromatography, TALON
(Aye and Stubbe, 2011); thus, a similar strategy was pursued
to isolate His6-a from mammalian cell lines subsequent to(C and D) Silver-stained-SDS-PAGE of SEC fractions, subsequent to ethanol
MW-standards.
(E) EM image of negatively stained complexes from the sample eluted at 17 min
(F) EM image of negatively stained complexes of recombinant (r)-His6-a incubate
(G) ISAC averages of a6 isolated from ClF-treated cells.
(H) ISAC averages derived from (F) were matched with the averages in (G).
(I) Averages in (G and H) correspond with 2D projections of an a6 model de
6.6 A˚-resolution X-ray structure of yeast a6 (Fairman et al., 2011). Scale bar corr
Chemistry & Biology 19,transfection (Cassette A, Figure 2A and Table S1B). The opti-
mized strategy led to the isolation of a (>95% pure as judged
by SDS-PAGE) with activity similar to that of recombinant
enzyme (Aye and Stubbe, 2011), and its identity was further
confirmed by western blot (Figures 2B and 2D, and Figures
S1D–S1B and S1D-C). Typical yields from COS-1 and HEK293
cell lines ranged from 24 mg a from a 75 cm2 of confluent
monolayer culture.
a Inhibited by ClFD(T)P or dATP in Lysates,
but Only Drug-Induced a6 Survives
We initially examined whether preassembled-a6 (formed by
treatment of r-His6-a with ClFD(T)P; Aye and Stubbe, 2011)
could be added to COS-1 lysates and isolated intact using
TALON. SEC of isolated protein and western blot analysis of
eluted fractions revealed that hexameric states were observed
(Figure S2A). We then showed that ectopically expressed
functional His6-a in mammalian cells is also responsive to ClF-
nucleotides as expected from in vitro studies with r-His6-a (Aye
and Stubbe, 2011). Treatment of COS-1 cell lysates with
ClFD(T)P (2 mM) depleted lysate activities (Figure S2B) and the
a6 state(s) assembled in lysates were retained throughout the
purification (Figure S2C). These outcomes contrast with controls
without ClFD(T)P or when saturating amounts of dATP (20 mM)
(Kashlan and Cooperman, 2003; Rofougaran et al., 2006;
Fairman et al., 2011; Aye and Stubbe, 2011), were added to
the lysates under identical conditions.
ClF Treatment Drives Persistent Hexamerization
in Live Mammalian Cells
Our subsequent studies employed the bicistronic plasmid
(Cassette A, Figure 2A and Table S1B) because it gave the high-
est total protein yield and the native His6-tagged-a could be
isolated from the lysate. As in the crosslinking experiments
above that used the monocistronic plasmid, COS-1 cells were
incubated with ClF for 3 hr where high cell viability was still
maintained (Figures S1C and S1D-A). However, because
a expression was now higher (Figure S1B-C), 5 mM ClF was
used as opposed to the 0.05 mM in crosslinking experiments.
After cell lysis and TALON purification of His6-a, the oligomeric
state of eluted protein, from both treated and untreated cells,
was determined by SEC. The SEC profile of the isolated protein
from drug-treated cells closely resembled a6 characterized
in vitro (Aye and Stubbe, 2011) and was markedly different
from the isolated a from untreated cells or the recombinant
protein in the absence of ClFD(T)P. Proteins in SEC fractions
were ethanol precipitated and analyzed by gel electrophoresis
and silver-staining (Chevallet et al., 2006), confirming the pres-
ence of a homogeneous hexameric a in the experiment and
not in the control (Figures 3A–3D).precipitation, from ClF-treated (C) and untreated cells (D). Arrows indicate
in (A).
d with ClFDP in vitro. Similar results were obtained with ClFTP.
rived by superimposing 3 copies of a human r-a2 X-ray structure onto the
esponds to 100 nm in (E) and (F) or 314 A˚ in (G), (H), and (I).
799–805, July 27, 2012 ª2012 Elsevier Ltd All rights reserved 803
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Clofarabine Induces hRNR Hexamers in Live CellsSingle Particle Electron Microscopy Directly Identifies
Drug-Induced Hexameric Assemblies
To gain further insight into the subunit organization of a6
assembled in live cells, we turned to EM analysis of
complexes isolated from ClF-treated cells subsequent to
both affinity purification and SEC characterization (Figure 3E).
For comparison, we also collected EM images of r-His6-
a incubated with ClFDP in vitro (Aye and Stubbe, 2011) (Fig-
ure 3F). Images were analyzed using a recently described
iterative stable alignment and clustering (ISAC) algorithm
(Yang et al., 2012). ISAC averages of the a6 complexes from
ClF-treated cells reveal a subunit arrangement that strikingly
resembles the complex formed in vitro (Figures 3G and 3H,
respectively, and Figure S2D). Furthermore, ISAC averages
from both preparations closely resemble projections of
an atomic model of human r-a6 generated by arranging
six copies of the human r-a X-ray structure with dATP/TTP
bound according to the 6.6 A˚-resolution X-ray structure of a6
from yeast (Fairman et al., 2011) (Figure 3I). These observa-
tions establish that the drug-induced complexes formed in
cells or assembled in vitro adopt similar trimer-of-dimers
architectures.
ClFD(T)P Induces Kinetically Stable Hexamers
Persisting beyond Inhibitor Dissociation
Given the isolation procedure, the a-hexamers isolated from live
cells are likely unliganded. To support this proposal, [8-3H]-
ClFD(T)P were synthesized (see Supplemental Experimental
Procedures) and SEC experiments were replicated using r-
His6-a in vitro (Figure S3A). No observable radioactivity was
associated with the ClFTP-induced hexameric protein fractions.
In the case of [8-3H]-ClFDP, 1.0 ± 0.2 ClFDP/a6 was detected at
1.5 or 15 mM a, consistent with its slow release from E,ClFDP*
(Aye and Stubbe, 2011). We additionally showed that in the
case with ClFTP, the SEC-eluted unliganded-a6 persists in this
state, even subsequent to overnight standing at 4C in 5 mM
DTT (Figure S3B).
DISCUSSION
Our data establish that alterations of (a2)m quaternary equilibria
observed in vitro with ClFD(T)P can be recapitulated in
live cells. They demonstrate ClF-nucleotide(s)-driven in-cell
assembly of persistent hexamers, even in the presence of
dNTP/ATP pools and limited amounts of (b2)n/p53(b2)n (The-
lander, 2007). Remarkably the hexameric states remain kineti-
cally stable subsequent to cell lysis and affinity isolation. The
markedly different results observed with the nontreated lysates
and dATP-treated controls emphasize that hexamerization
is ClFD(T)P-mediated and most likely cell-type-independent.
Our results further suggest that small-molecule-promoted
persistent oligomerization is a new avenue, to our knowledge,
to target hRNR. Once the molecular basis for these inhibitory
states are understood, additional small molecules might be
discovered that stabilize these states and function as new
types of hRNR inhibitors. Finally, the IRES-mediated dual-
expression system that we have built here (Figure 2A) provides
a platform to study further aspects of hRNR in live mammalian
cells.804 Chemistry & Biology 19, 799–805, July 27, 2012 ª2012 Elsevier LSIGNIFICANCE
Human ribonucleotide reductase (hRNR), an essential
enzyme in DNA synthesis, is a proven target of the leukemia
drug Clofarabine (ClF). Two distinct subunits, (a2)m and (b2)n,
complete the active unit required for the catalysis of NDP
(N = A,C,G,U) reduction to dNDPs. Oligomeric equilibria of
(a2)m governed by binding of various NDP substrate/(d)NTP
allosteric effector pairs remain a poorly understood area of
mammalian RNR, even in vitro, and the relevance of these
states [(a2)m(b2)n; m, n = 1–3] is yet to be established in
the cell. Our previous biochemical studies have demon-
strated that hRNR inhibition by ClFD(T)P is coupled to
a-hexamerization in vitro. We now report that this mecha-
nism is operative in mammalian cells: a-targeted inhibition
by phosphorylated ClF involves in-cell assembly of kineti-
cally stable hexamers that persist beyond inhibitor depar-
ture. The oligomeric state of a isolated from live cells
exposed to ClF has been analyzed by chemical crosslinking,
size exclusion chromatography, and single-particle electron
microscopy. Together, these studies reveal that a-hexame-
rization in vivo occurs independently of (b2)n, and even in the
presence of various pools of NDP substrates and (d)NTP
allosteric effectors. This is in stark contrast to previously
characterized nucleotide analog inhibitors of RNR, where
(a2)m(b2)n holocomplex formation is a prerequisite for the
initiation of mechanism-based inactivation. Given the con-
stitutive expression of a in mammalian cells and the con-
trasting expression of b, which is primarily S-phase specific,
our studies unveil an avenue to downregulate activity of this
key enzyme, solely by targeting (a2)m through persistent
oligomerization. The approach we have established here
also represents a potentially useful strategy to characterize
modulations of RNR quaternary structure in live mammalian
cells in response to external stimuli. In a broader context,
these findings present an interesting example of nonnatural
small-molecule(s)-induced perturbation of protein quater-
nary structures in cells, demonstrated using the clinically
important drug, ClF.
EXPERIMENTAL PROCEDURES
See Supplemental Information for experimental procedures and additional
supporting figures.
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